170 related articles for article (PubMed ID: 28049758)
1. Identification of mouse cathepsin K structural elements that regulate the potency of odanacatib.
Law S; Andrault PM; Aguda AH; Nguyen NT; Kruglyak N; Brayer GD; Brömme D
Biochem J; 2017 Feb; 474(5):851-864. PubMed ID: 28049758
[TBL] [Abstract][Full Text] [Related]
2. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
Stone JA; McCrea JB; Witter R; Zajic S; Stoch SA
Br J Clin Pharmacol; 2019 Jun; 85(6):1072-1083. PubMed ID: 30663085
[TBL] [Abstract][Full Text] [Related]
3. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.
Leung P; Pickarski M; Zhuo Y; Masarachia PJ; Duong LT
Bone; 2011 Oct; 49(4):623-35. PubMed ID: 21718816
[TBL] [Abstract][Full Text] [Related]
4. An allosteric site enables fine-tuning of cathepsin K by diverse effectors.
Novinec M; Rebernik M; Lenarčič B
FEBS Lett; 2016 Dec; 590(24):4507-4518. PubMed ID: 27859061
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis.
Duong le T; Leung AT; Langdahl B
Calcif Tissue Int; 2016 Apr; 98(4):381-97. PubMed ID: 26335104
[TBL] [Abstract][Full Text] [Related]
6. Rat cathepsin K: Enzymatic specificity and regulation of its collagenolytic activity.
Lecaille F; Chazeirat T; Bojarski KK; Renault J; Saidi A; Prasad VGNV; Samsonov S; Lalmanach G
Biochim Biophys Acta Proteins Proteom; 2020 Feb; 1868(2):140318. PubMed ID: 31740411
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits.
Pennypacker BL; Oballa RM; Levesque S; Kimmel DB; Duong LT
BMC Musculoskelet Disord; 2013 Dec; 14():344. PubMed ID: 24321244
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible.
Zhuo Y; Gauthier JY; Black WC; Percival MD; Duong LT
Bone; 2014 Oct; 67():269-80. PubMed ID: 25038310
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
Mukherjee K; Chattopadhyay N
Biochem Pharmacol; 2016 Oct; 117():10-9. PubMed ID: 27106079
[TBL] [Abstract][Full Text] [Related]
10. A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K.
Panwar P; Søe K; Guido RV; Bueno RV; Delaisse JM; Brömme D
Br J Pharmacol; 2016 Jan; 173(2):396-410. PubMed ID: 26562357
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of inhibitors of cathepsin K on dedifferentiated chondrocytes.
Yuan XY; Ren Z; Wu Y; Bougault C; Brizuela L; Magne D; Buchet R; Mebarek S
Bioorg Med Chem; 2019 Mar; 27(6):1034-1042. PubMed ID: 30773420
[TBL] [Abstract][Full Text] [Related]
12. Structural requirements for the collagenase and elastase activity of cathepsin K and its selective inhibition by an exosite inhibitor.
Sharma V; Panwar P; O'Donoghue AJ; Cui H; Guido RV; Craik CS; Brömme D
Biochem J; 2015 Jan; 465(1):163-73. PubMed ID: 25279554
[TBL] [Abstract][Full Text] [Related]
13. A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture.
Pirapaharan DC; Søe K; Panwar P; Madsen JS; Bergmann ML; Overgaard M; Brömme D; Delaisse JM
Calcif Tissue Int; 2019 Jan; 104(1):92-101. PubMed ID: 30194476
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 pooled PK/PD analysis of bone resorption biomarkers for odanacatib, a Cathepsin K inhibitor.
Zajic S; Stoch SA; McCrea JB; Witter R; Fayad GN; Martinho M; Stone JA
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):473-484. PubMed ID: 32647957
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: Commonalities and differences.
Brömme D; Panwar P; Turan S
Expert Opin Drug Discov; 2016; 11(5):457-72. PubMed ID: 27001692
[TBL] [Abstract][Full Text] [Related]
16. An Ectosteric Inhibitor of Cathepsin K Inhibits Bone Resorption in Ovariectomized Mice.
Panwar P; Xue L; Søe K; Srivastava K; Law S; Delaisse JM; Brömme D
J Bone Miner Res; 2017 Dec; 32(12):2415-2430. PubMed ID: 28745432
[TBL] [Abstract][Full Text] [Related]
17. Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib.
Rünger TM; Adami S; Benhamou CL; Czerwiński E; Farrerons J; Kendler DL; Mindeholm L; Realdi G; Roux C; Smith V
J Am Acad Dermatol; 2012 Mar; 66(3):e89-96. PubMed ID: 21571394
[TBL] [Abstract][Full Text] [Related]
18. Identification of substrate-specific inhibitors of cathepsin K through high-throughput screening.
Law S; Du X; Panwar P; Honson NS; Pfeifer T; Roberge M; Brömme D
Biochem J; 2019 Feb; 476(3):499-512. PubMed ID: 30622151
[TBL] [Abstract][Full Text] [Related]
19. Highly potent inhibitors of cathepsin K with a differently positioned cyanohydrazide warhead: structural analysis of binding mode to mature and zymogen-like enzymes.
Benýšek J; Buša M; Rubešová P; Fanfrlík J; Lepšík M; Brynda J; Matoušková Z; Bartz U; Horn M; Gütschow M; Mareš M
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):515-526. PubMed ID: 35144520
[TBL] [Abstract][Full Text] [Related]
20. [Cathepsin K antagonists: preclinical and clinical data].
Gamsjäger M; Resch H
Wien Med Wochenschr; 2015 Feb; 165(3-4):65-70. PubMed ID: 25572547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
